title: [Pharmacotherapy in benign prostatic hyperplasia].
abstract: To avoid an operation, there are innumerable pharmaceutics on sale for the treatment of the benign prostatic hyperplasia. For this reason we have to distinguish between pharmaceutics without effect and those with proved action on the hyperplastic metaplasia. The symptoms can often be lessened at the initial stage by way of drugs with ineffective action (phytopharmaceutics); there could not yet be proved any effect on the biology of the prostatic hyperplasia. We make use of this therapeutic at the initial stage. Some of the substances with a real effect (alpha-receptor blockers, alpha-reductase inhibitors) do not necessarily provide an effective result in all cases. In addition to that, these therapeutics of partially serious side effects have to be taken for life. Here immediately arises the question of how it could be managed financially.
authors.affiliation: Urologische Klinik, Universitätsspital Zürich.
authors.forename: D
authors.initials: D
authors.lastname: Hauri
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D010946:Plants, Medicinal; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D007987:Gonadotropin-Releasing Hormone